Vaxcyte Corporate Presentation
30
50
VAX-A1: Group A Strep Conjugate Vaccine Program
Monovalent Conjugate Vaccine Designed to Provide Universal Protection
о
Unmet
Need
VAX-A1:
Broad-spectrum,
Monovalent
Conjugate Vx
Program
Status
Group A Strep causes 700M global annual cases of pharyngitis (strep throat) and increases risk of severe invasive infections
such as sepsis, necrotizing fasciitis and toxic shock syndrome
• Upgraded CDC threat given significant source of antibiotic Rxs driving resistance which has nearly tripled in past decade
Responsible for post-infectious immune-mediated rheumatic heart disease leading to over 300K deaths in 2015
•
Highly prevalent in children and rate of invasive disease in adults > 65 has more than doubled (exceeding IPD rate in adults)
Designed to confer robust, boostable and durable protection against a broad spectrum of subtypes of Group A Strep
• Leverages site-specific conjugation to disease-specific carrier to expose mapped T- and B-cell epitopes
•
Proprietary conserved antigen - Polyrhamnose - conjugated to an immunogenic disease-specific carrier along with two
conserved virulence factors
Partially funded by grant from CARB-X (consortium of BMGF, Wellcome Trust, US Biodefense Agency (BARDA)); add'l
August 2021 award of $3.2M toward IND-enabling activities; total potential funding of up to $29.7M inclusive of grants to date
• Nominated final vaccine candidate in 1Q 2021
Initiated IND-enabling activities in 2H 2021
25-
© 20
Resistance tripled
over past decade
100
80-
"
Active immunization
Mock
-
- SLO + C5a pep
Key Data
BMGF = Bill & Melinda Gates Foundation.
% Resistance
15
10-
CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: US Department of Health an 20 2013
5
2010
2011
2014
Services,
2015
CBC
202016
2017
Percent survival
60
L
40
20
0
0
24
48
72
Time (h)
96
120
- SpyAD-GACPR
VAX-A1 (SLO + C5a pep
+ SpyAD-GACPR)View entire presentation